These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19702545)

  • 1. Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.
    Sugioka N; Fujimoto K; Tanaka Y; Fukushima K; Ito Y; Kokuhu T; Okamoto M; Yoshimura N; Takada K
    Drug Metab Lett; 2009 Aug; 3(3):152-61. PubMed ID: 19702545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia.
    Sugioka N; Takai M; Yoshida K; Yasuda K; Fukushima K; Kokuhu T; Okamoto M; Yoshimura N; Takada K
    J Clin Pharm Ther; 2010 Jun; 35(3):323-32. PubMed ID: 20831533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
    Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
    Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients.
    Kelles A; Van Damme-Lombaerts R; Tjandra-Maga TB; Van Damme B
    Transpl Int; 1996; 9(6):546-50. PubMed ID: 8914233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center.
    Okada A; Ushigome H; Kanamori M; Morikochi A; Kasai H; Kosaka T; Kokuhu T; Nishimura A; Shibata N; Fukushima K; Yoshimura N; Sugioka N
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1111-1119. PubMed ID: 28620753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter--why cyclosporine is monitored by C(2) level and tacrolimus by trough level--.
    Takeuchi H; Matsuno N; Senuma K; Hirano T; Yokoyama T; Taira S; Kihara Y; Kuzuoka K; Konno O; Jojima Y; Mejit A; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Ashizawa T; Nagao T; Toraishi T; Okuyama K; Oka K; Unezaki S
    Biol Pharm Bull; 2008 Jan; 31(1):90-4. PubMed ID: 18175948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
    Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
    Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
    J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients.
    Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
    Transplant Proc; 2003 Jun; 35(4):1300-3. PubMed ID: 12826143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients.
    Kabasakul SC; Clarke M; Kane H; Karsten J; Clark G
    Pediatr Nephrol; 1997 Jun; 11(3):318-21. PubMed ID: 9203180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
    Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
    J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.
    Kokuhu T; Fukushima K; Ushigome H; Yoshimura N; Sugioka N
    Int J Med Sci; 2013; 10(12):1665-73. PubMed ID: 24151438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cyclosporine A after massive hepatectomy: a hint for small-for-size graft in living donor liver transplantation.
    Shinohara H; Shimada M; Ogasawara T; Morine Y; Ikemoto T; Imura S; Fujii M
    Dig Dis Sci; 2007 Oct; 52(10):2490-6. PubMed ID: 17431772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.